| Abstrakt: |
This article is an editorial that discusses the topic of immune evasion in cancer. It highlights the importance of understanding the interaction between immune cells and cancer cells in order to improve cancer patient outcomes. The editorial mentions several research papers that propose novel preclinical models, biomarkers, and treatment approaches to address immune evasion in different types of cancer. These studies explore potential biomarkers, such as mitogen-activated protein kinase-activated protein kinase 2 (MK2), plasminogen activator inhibitor-1 (PAI-1), membrane palmitoylated protein 6 (MPP6), and intercellular adhesion molecule 1 (ICAM1), that may contribute to immune evasion in various cancers. Additionally, the editorial discusses the development of predictive algorithms and models based on immune evasion biomarkers to support clinical diagnosis and treatment decisions. The ultimate goal is to improve cancer diagnosis, prognosis, and treatment outcomes by better understanding the complex interaction between immune cells and cancer. [Extracted from the article] |
